ABTAbbott Laboratories
$103.70-18% 1Y
$103.70
$82.5652 weeks$129.12
The financials
Abbott Laboratories by the numbers
Abbott Laboratories (ABT) reported revenue of $12.6B in Q2 2026 (quarter ended Jun 30, 2026), up 13% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $928M (7.4% of revenue). For the full year FY2025, revenue was $44.3B (+5.7% year on year) and net income $6.52B. Its largest segment in Q2 2026 was Nutritional Products at $525M, 41% of the disclosed total, ahead of Diagnostic Products at 29%. The next results filing is expected around Jan 21, 2027, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $12.6B | $11.1B | +13% |
| Gross profit | $7.27B | $6.29B | +16% |
| Operating income | $1.69B | $2.05B | −17% |
| Net income | $928M | $1.78B | −48% |
| Diluted EPS | $0.53 | $1.01 | −48% |
| Operating | Revenue | Share |
|---|---|---|
| Nutritional Products | $525M | 41% |
| Diagnostic Products | $377M | 29% |
| Medical Devices | $377M | 29% |
Business segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $1.28B (+6.9%)
Medical Devices grew +11% year on yearNutritional Products -11% year on year
Segment Latestquarter on quarteryear on year
- Nutritional Products$525.0M$525.0Mquarter on quarter +2.7%year on year -11%+2.7%-11%
- Diagnostic Products$377.0M$377.0Mquarter on quarter +8.6%year on year +7.4%+8.6%+7.4%
- Medical Devices$377.0M$377.0Mquarter on quarter +11%year on year +11%+11%+11%
- Established Pharmaceutical Products$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
Medical Devices
The closest names by size in the same industry